NCT05599789 2025-02-18
KeyPemls-004
Peking Union Medical College Hospital
Phase 2 Unknown
Clinical Trials
4,147 trialsNCT06678230 2024-11-07
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Phase 2 Unknown
NCT02236910 2024-10-15
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Unknown
NCT06322095 2024-10-01
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
Phase 2 Unknown
NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06586697 2024-09-19
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
Henan Cancer Hospital
Phase 2 Unknown
NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
NCT06149169 2024-08-21
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT03612232 2024-08-19
CaboACC
Wuerzburg University Hospital
Phase 2 Unknown
NCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Unknown
NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT06487715 2024-07-05
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06311695 2024-06-24
CESM
European Institute of Oncology
Phase 2 Unknown
NCT03818386 2024-06-14
NANORAD2
University Hospital, Grenoble
Phase 2 Unknown
NCT05638451 2024-06-05
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Phase 2 Unknown
NCT06136065 2024-06-04
FAPI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Unknown
NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT06406673 2024-05-09
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06078306 2024-04-22
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03425565 2024-04-12
PEACOCC
University College, London
Phase 2 Unknown
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT06353581 2024-04-09
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
Yonsei University
Phase 2 Unknown
NCT06345300 2024-04-03
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06341530 2024-04-02
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT06341660 2024-04-02
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Guangzhou Institute of Respiratory Disease
Phase 2 Unknown
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Unknown
NCT06339242 2024-04-01
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
Phase 2 Unknown
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT06334757 2024-03-28
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Henan Cancer Hospital
Phase 2 Unknown
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Unknown
NCT06332287 2024-03-27
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
Phase 2 Unknown
NCT04543695 2024-03-26
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT06331650 2024-03-26
A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease
Phase 2 Unknown
NCT06328049 2024-03-25
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC
Taixing People's Hospital
Phase 2 Unknown
NCT06322563 2024-03-21
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06079931 2024-03-20
The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT05801133 2024-03-15
Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
Hubei Cancer Hospital
Phase 2 Unknown
NCT06176339 2024-03-15
Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"
Mansoura University
Phase 2 Unknown
NCT04163419 2024-03-13
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Massachusetts General Hospital
Phase 2 Unknown
NCT04249739 2024-03-13
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
Samsung Medical Center
Phase 2 Unknown
NCT05442632 2024-03-13
Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
Fudan University
Phase 2 Unknown
NCT06033820 2024-03-13
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Phase 2 Unknown
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT03951337 2024-03-12
64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)
Institut Cancerologie de l'Ouest
Phase 2 Unknown
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT05004974 2024-03-12
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Unknown
NCT06277674 2024-03-08
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Guangzhou University of Traditional Chinese Medicine
Phase 2 Unknown
NCT06301828 2024-03-08
Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown